Herzuma (CT-P6) / trastuzumab biosimilar
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Herzuma (CT-P6) / trastuzumab biosimilar, covering 2025-04-02 to 2025-04-02. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice [NA]